05-11-01

Express Mail Label No.: EV942366599US

Date of Deposit: May 9, 2007

Attorney Docket No. 24852-503 NATL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Miller, et al.

CONFIRMATION NUMBER:

Not yet assigned

SERIAL NUMBER:

10/574,992

EXAMINER:

Not yet assigned

I.A. FILING DATE:

October 8, 2004

INT'L APPLICATION NO:

PCT/US04/033386

PRIORITY DATE:

October 9, 2003

ART UNIT:

Not yet assigned

FOR:

Thiophene and Benzothiophene Hydroxamic Acid Derivatives

L STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

- 1. Information Disclosure Statement (2 pages) in duplicate;
- 2. Modified Form PTO-1449 (2 pages); in duplicate;
- 3. Cited References A1-A11; B1-B4; C1-C51; and
- 4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (212) 935-3000.

The Commissioner is authorized to charge any fees that may be due or to credit any overpayment of same to the undersigned's account, Deposit Account No. 50-0311, Customer Number: 35437, Reference Number: 24852-503 NATL.

Respectfully submitted,

Dated: May 9, 2007

chelle A Awamoto Ivor R. Elrifi, Reg. No. 39,529

Michelle A. Iwamoto, Reg. No. 55,296

Attorneys/Agents for Applicants

c/o MINTZ, LEVIN, et al. 666 Third Avenue-24th Floor

New York, New York 10017

Telephone: (212) 983-3000

Telefax: (212) 983-3115

Express Mail Label No.: EV942366599US

Date of Deposit: May 9, 2007

Attorney Docket No. 24852-503 NATL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Miller, et al. CONFIRMATION NUMBER: Not yet assigned

SERIAL NUMBER: 10/574,992 EXAMINER: Not yet assigned

I.A. FILING DATE: October 8, 2004 INT'L APPLICATION NO: PCT/US04/033386

PRIORITY DATE: October 9, 2003 ART UNIT: Not yet assigned

FOR: Thiophene and Benzothiophene Hydroxamic Acid Derivatives

MAIL STOP AMENDMENT

Commissioner for Patents

R.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. In accordance with MPEP §609(III)(A)(2), copies of the cited U.S. patents and U.S. publications are not required.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-identified application. Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims. It is also respectfully requested that the Examiner initial, sign and date, and return a copy of the signed modified Form PTO-1449 with the next U.S. PTO communication, to evidence that the cited information has been fully considered by the U.S. Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Express Mail Label No.: EV942366599US

Date of Deposit: May 9, 2007

Attorney Docket No. 24852-503 NATL

The order of presentation of the references should not be construed as an indication of the importance of the references. The Examiner is urged to form his/her own conclusion regarding the relevance of the cited information.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 24852-503 NATL, Customer No. 35437.

Respectfully submitted,

Dated: May 9, 2007

nechello A Twamots Ivor R. Elrifi, Reg. No. 39,529

Michelle A. Iwamoto, Reg. No. 55,296

Attorneys/Agents for Applicants

c/o MINTZ, LEVIN, *et al.* 666 Third Avenue-24th Floor New York, New York 10017

Telephone: (212) 983-3000

Telefax: (212) 983-3115

Attorney Docket No. 24852-503 NATL Page 1 of 2

Express Mail Label No.: EV942366599US

Date of Deposit: May 9, 2007

Please type a plus sign (+) in this box

PTO/SB (12-97)
OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

d Form 1449/P10	Application Number	10/574,992
	International Application Number	PCT/US04/033386
	I.A. Filing Date	October 8, 2004
INFORMATION DISCLOSURE	Priority Date	October 9, 2003
STATEMENT BY APPLICANT	First Named Inventor	Miller
	Group Art Unit / Conf. No.:	Not Yet Assigned
(use as many sheets as necessary)	Examiner Name	Not Yet Assigned
	Attorney Docket Number	24852-503 NATL
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	International Application Number I.A. Filing Date INFORMATION DISCLOSURE STATEMENT BY APPLICANT First Named Inventor Group Art Unit / Conf. No.: Examiner Name

	U.S. PATENT DOCUMENTS						
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
	A1	4,522,811	06/11/85	Eppstein, et al.	514	2	07/08/82
	A2	5,369,108	11/29/94	Breslow, et al.	514	266	10/04/91
	A3	5,608,108	03/04/97	Marks, et al.	562	621	04/17/95
	A4	5,700,811	12/23/97	Breslow, et al.	514	314	05/19/94
	A5	5,932,616	08/03/99	Breslow, et al.	514	532	04/04/94
	A6	6,087,367	07/11/00	Breslow, et al.	514	266	05/18/99
	A7	6,511,990	01/28/03	Breslow, et al.	514	314	08/24/00
	A8	6,541,661	04/01/03	Delorme, et al.	560	318	11/22/00
	A9	2003/0013757	01/16/03	Leser-Reiff, et al.	514	448	06/11/02
	A10	2003/0235588	12/25/03	Richon, et al.	514	575	02/14/03
	A11	2004/0087657	05/06/04	Richon, et al.	514	575	10/16/02

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite Foreign Patent Document No. Office Number			Name of Patentee(s) or Applicant(s)	Date of Publication	English Yes No	
	B1	wo	97/11366	Merck & Co., Inc.	March 27, 1977	Х	
	B2	wo	98/48825	The Salk Institute for Biological Studies	November 5, 1998	X	
	В3	wo	00/08048	Fujisawa Pharmaceuticals Co., Ltd.	February 17, 2000	X	
	B4	wo	05/348800	Aton Pharma, Inc.	April 21, 2005	X	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.		
	C1	Abe, E., et al., Proc. Natl. Acad. Sci. (USA) 78: 4990-4994 (1981)		
	C2	Andrews et al., International J. Parasitology 30,761-768 (2000)		
	C3	Archer, S. et al., PNAS 95:6791-96 (1998)		
	C4	Brosch et al., Plant Cell 7, 1941-1950 (1995)		
	C5	Butler, L.M. et al., Cancer Res. 60:5165-5170 (2000)		
	C6	Cohen, L.A. et al., Anticancer Research 19:4999-5006 (1999)		
	C7	Cousens et al., J. Biol. Chem. 254,1716-1723 (1979)		
	C8	Darkin-Rattray et al., Proc. Natl. Acad. Sci. USA 93,13143-13147 (1996)		
	C9	Dressel, U. et al., Anticancer Research 20(2A):1017-22 (2000)		
	C10	Ebert, P. S., et al. Cancer Res. 36: 1809-1813 (1976)		
	C11	Finnin, M.S., et al., Nature 401:188-193 (1999)		
	C12	Frey et al, Bioorganic & Med. Chem. Lett., 12, 3443-3447 (2002)		
	C13	Friend, C., et al., Proc. Natl. Acad. Sci., U. S., 68:378-382 (1971)		
	C14	Grunstein, M., Nature, 389: 349-52 (1997)		
	C15	Guan et al., Cancer Research, 60,749-755 (2000)		
	C16	Hayashi, M., et al., Gann 70: 235-238 (1979)		

Express Mail Label No.: EV942366599US Date of Deposit: May 9, 2007

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C17	Huberman, E. et al., Proc. Natl. Acad. Sci. (USA) 76: 1293-1297 (1979)
	C18	Kijima et al., J Biol. Chem. 268,22429-22435 (1993)
	C19	Kim et al., Oncogene, 18: 2461-2470 (1999)
	C20	Koghe et al., Biochem. Pharmacol. 56: 1359-1364 (1998)
	C21	Kwon et al., PNAS 95: 3356-3361 (1998)
	C22	Lea et al., Anticancer Research, 15, 879-873 (1995)
	C23	Lin, R.J. et al., Nature 391:811-14 (1998)
	C24	Lotem, J., et al., Int. J. Cancer 15: 731-740 (1975)
	C25	Lotem, J. et al., Proc. Natl. Acad. Sci. (USA) 76: 5158-516) (1979)
	C26	Marks et al., Cancer Res. 47:659 (1987)
	C27	Marks, P.A. et al., J. Natl. Cancer Inst., 92:1210-1215 (2000)
	C28	McBain et al., Biochem. Pharm. 53: 1357-1368 (1997)
	C29	Metcalf, D., et al., Science, 229: 16-22 (1985)
	C30	Morin, M. J., et al., Cancer Res. 44: 2807-2812 (1984)
	C31	Nakajima et al., Ex. Cell Res. 241,126-133 (1998)
	C32	Qiu et al., Mol. Biol. Cell 11, 2069-2083 (2000)
	C33	Reuben, R. C., et al., Proc. Natl. Acad. Sci. (USA) 73: 862-866 (1976)
	C34	Richon et al., Proc. Natl. Acad. Sci. USA, 93:5705-5708 (1996)
	C35	Richon, V. M. et al., Proc. Natl. Acad. Sci., USA, 95:3003-3007 (1998)
	C36	Sachs, L., Nature (Lond.) 274: 535 (1978)
	C37	Saito et al., Proc. Natl. Acad. Sci. USA 96, 4592-4597 (1999)
	C38	Scher, W. et al., Exp. Hematol. 11: 490-498 (1983)
	C39	Scher, W., et al., Biochem. & Biophys. Res. Comm. 109: 348-354) (1982)
	C40	Schwartz, E. L. et al., Cancer Res. 42: 2651-2655 (1982)
	C41	Schwartz, E. L., et al., Cancer Res. 43: 2725-2730 (1983)
	C42	Schwartz, E. L., et al., Proc. Am. Assoc. Cancer Res. 24: 18 (1983)
	C43	Su et al., Cancer Research, 60: 3137-3142 (2000)
	C44	Sugano, H., et al., Bibl. Hematol. 39: 943-954 (1973)
	C45	Takenaga, K., et al., Cancer Res. 40: 914-919 (1980)
	C46	Tanaka, M., et al., Proc. Natl. Acad. Sci. (USA) 72: 1003-1006 (1975)
	C47	Terada, M., et al., Proc. Natl. Acad. Sci. (USA) 75: 2795-2799 (1978)
	C48	Van Lint, C. et al., Gene Expression 5:245-53 (1996)
	C49	Wang et al., Cancer Research, 59, 2766-2799 (1999)
	C50	Yoshida, M. et al., J. Biol. Chem., 265:17174-17179, (1990)
	C51	International Search Report for PCT/US04/33386 mailed June 8, 2005

continuation-in-part, and divisional applications).							
Examiner Signature		Date Considered					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

4030051v.1